/PRNewswire/ AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases.
/PRNewswire/ AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases.
Two biotechs are braving the roiling financial markets to raise money for clinical trials. AN2 Therapeutics is preparing for a pivotal test of its boron-based drug candidate for a rare, chronic lung disease. Okyo Pharma also filed IPO paperwork as it looks to advance to the clinic with its dry eye disease drug.
/PRNewswire/ AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious.
/PRNewswire/ AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious.